Now showing items 1-2 of 2
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
(Mol Genet Metab, 2013-02)
We investigated the feasibility of using recombinant human acid-α glucosidase (rhGAA, Alglucosidase alfa), an FDA approved therapy for Pompe disease, as a treatment approach for glycogen storage disease type III (GSD III). ...
Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events.
(Circ Cardiovasc Genet, 2010-04)
BACKGROUND: Molecular tools may provide insight into cardiovascular risk. We assessed whether metabolites discriminate coronary artery disease (CAD) and predict risk of cardiovascular events. METHODS AND RESULTS: We performed ...